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PAR-1 Kinase Plays an Initiator Role in a
Temporally Ordered Phosphorylation
Process that Confers Tau Toxicity in Drosophila
2000; Hardy and Selkoe, 2002). Studies in transgenic
mice have shown that expression of mutant human tau
(h-tau) alone could result in tangle pathology and neu-
ronal loss without accompanying plaque pathology
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amyloid deposits in these animals could further promote
NFT formation, suggesting that the two lesions could
be causally linked (Gotz et al., 2001; Lewis et al., 2001;Summary
Oddo et al., 2003). Together, these studies support the
notion that abnormality in tau can be a direct cause ofMultisite hyperphosphorylation of tau has been impli-
neurodegeneration.cated in the pathogenesis of neurodegenerative dis-
Little is known about the molecular and cellular mech-eases including Alzheimer’s disease (AD). However,
anisms underlying tau-mediated cellular toxicity. Thethe phosphorylation events critical for tau toxicity and
presence of abnormally phosphorylated tau in NFT sug-mechanisms regulating these events are largely un-
gests that an imbalance in tau phosphorylation/dephos-known. Here we show that Drosophila PAR-1 kinase
phorylation may be pathogenic. A number of proteininitiates tau toxicity by triggering a temporally ordered
kinases and phosphatases have been shown to regulatephosphorylation process. PAR-1 directly phosphory-
h-tau phosphorylation in vitro. These include GSK-3,lates tau at S262 and S356. This phosphorylation event
MAP kinase, Cdk2 and 5, PKA, CaMKII, microtubule-is a prerequisite for the action of downstream kinases,
affinity regulating kinase (MARK), and protein phospha-including glycogen synthase kinase 3 (GSK-3) and
tase 1, 2A, 2B, and 2C (Goedert et al., 1995; Lee etcyclin-dependent kinase-5 (Cdk5), to phosphorylate
al., 2001; Mandelkow, 1999). Despite a large body ofseveral other sites and generate disease-associated
biochemical studies, surprisingly little is known aboutphospho-epitopes. The initiator role of PAR-1 is further
the in vivo roles of these enzymes in conferring tauunderscored by the fact that mutating PAR-1 phos-
toxicity. Studies using transgenic mice overexpressingphorylation sites causes a much greater reduction of
Cdk5 or GSK-3 have implicated these two kinases inoverall tau phosphorylation and toxicity than mutating
tau phosphorylation, aggregation, and tangle formationS202, one of the downstream sites whose phosphory-
(Lucas et al., 2001; Noble et al., 2003), but in vivo loss-lation depends on prior PAR-1 action. These findings
of-function analyses are needed to verify the involve-begin to differentiate the effects of various phosphory-
ment of these kinases in tau-mediated neuronal pathol-lation events on tau toxicity and provide potential ther-
ogies.apeutic targets.
Drosophila has recently established itself as a model
system for studying human neurodegenerative disor-
Introduction
ders. Fly models of tauopathy have been created by
expressing wild-type or FTDP-linked mutant forms of
Accumulation of proteins with abnormal conformation h-tau (Jackson et al., 2002; Wittmann et al., 2001). Using
is a feature shared by many neurodegenerative dis- such models and based largely on overexpression ex-
eases. In tauopathies, the microtubule (MT) binding pro- periments, it was shown that Shaggy (GSK-3) can pro-
tein tau forms prominent intracellular aggregates known mote NFT pathology in photoreceptor neurons (Jackson
as neurofibrillary tangles (NFT) (Feany and Dickson, et al., 2002). Whether GSK-3 and NFT are necessary
1996; Goedert, 1998; Lee et al., 2001). Tau is normally a for tau-mediated neurodegeneration, however, remains
highly soluble protein enriched in axons, but it becomes uncertain. Other studies have shown that tau-mediated
abnormally phosphorylated and insoluble in NFT. While neurodegeneration could occur without NFT and that
these observations provide circumstantial evidence that GSK-3-induced tau hyperphosphorylation in mice
tau abnormalities may lead to neuronal dysfunction and could correlate inversely with neuropathology (Spittaels
degeneration, direct evidence was not available until et al., 2000; Wittmann et al., 2001).
the discovery that mutations in tau are associated with Critical testing for a functional role of phosphorylation
frontotemporal dementia with parkinsonism linked to in tau-mediated neuropathology will require identifying
chromosome 17 (FTDP-17) (Foster et al., 1997; Hutton the physiological tau kinase and assessing the conse-
et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998). quence of removing this kinase activity on the disease
NFT is also a pathological hallmark of AD, where NFT process. Through loss-of-function and overexpression
often but not always surround amyloid plaques com- genetic studies and biochemical analysis, we now show
posed of amyloid  peptides (Braak and Braak, 1991; that PAR-1 is a physiological tau kinase that plays a
Mandelkow and Mandelkow, 1998). It is still controver- central role in regulating tau phosphorylation and toxic-
sial as to which pathology, the NFT or amyloid plaque, ity in Drosophila. PAR-1 is a Ser/Thr kinase originally
is the primary cause of neuronal loss in AD (Davies, identified in C. elegans for its role in regulating cell polar-
ity and asymmetric cell division (Guo and Kemphues,
1995). PAR-1 homologs have been found in eukaryotes*Correspondence: bingwei@stanford.edu
ranging from yeast to mammals and exert essential cel-1Present Address: Department of Pathology, Stanford University
School of Medicine, Stanford, California 94305. lular and developmental functions. MARK kinase, the
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mammalian homolog of PAR-1, regulates MT dynamics, cell patterning, which often leads to secondary neuronal
apoptosis. To distinguish between these possibilities,epithelial cell polarity, and neuronal differentiation (Bier-
nat et al., 2002; Bohm et al., 1997; Drewes et al., 1997). we first tested whether overexpression of PAR-1 specifi-
cally in postmitotic neurons is sufficient to cause photo-Drosophila PAR-1 plays important roles in MT organiza-
tion, oocyte differentiation, anterior-posterior axis for- receptor degeneration. For this we used the elav-GAL4
driver to direct PAR-1 expression. Resulting elav-mation, and Wingless signaling (Cox et al., 2001; Shul-
man et al., 2000; Sun et al., 2001; Tomancak et al., 2000). GAL4UAS-PAR-1 flies exhibited a mild rough eye and
loss of photoreceptor neuron phenotype (Figures 1HWhile analyzing the neuronal function of PAR-1, we
found that Drosophila PAR-1 is a physiological kinase and 1J). To further address the cell type specificity and
to distinguish between neurodevelopmental or neurode-for fly tau and h-tau. Overexpression of PAR-1 leads
to elevated tau phosphorylation and enhanced toxicity, generative mechanisms of PAR-1-induced toxicity, we
used a heat shock-GAL4 driver to direct PAR-1 overex-whereas removing PAR-1 function or mutating PAR-1
phosphorylation sites in tau abolishes tau toxicity. Fur- pression. Induction of ubiquitous PAR-1 overexpression
by daily heat shock treatment starting from first instarthermore, we have uncovered an initiator role for PAR-1
in a multisite phosphorylation process that generates larval stage resulted in animals with rough eyes and
accompanying photoreceptor loss (Figures 1K and 1N).pathogenic forms of tau. In this process, phosphoryla-
tion by PAR-1 precedes and is obligatory for down- The animals are otherwise normal externally. Heat shock
induction starting from pupae or young adult stages,stream phosphorylation events, including those carried
out by GSK-3 and Cdk5, to generate toxic tau. Consis- when photoreceptor neurons are fully differentiated,
also resulted in a photoreceptor loss phenotype (Figurestent with PAR-1 playing an initiator role in the process,
mutating PAR-1 phosphorylation sites causes a much 1L, 1O, and 1P). Together, these results indicate that
PAR-1 overexpression-induced toxicity is relatively spe-more dramatic reduction of overall tau phosphorylation
and toxicity than mutating one of the downstream Cdk5/ cific to photoreceptor neurons and that this toxicity is
mediated at least in part through a progressive degener-GSK-3 phosphorylation sites. These findings have im-
portant implications for understanding the biogenesis ation mechanism.
of pathogenic tau in neurons and for developing mecha-
nism-based therapeutic strategies. Genetic Interaction between PAR-1 and Tau
The degeneration phenotype induced by PAR-1 overex-
pression could be mediated by abnormal phosphoryla-Results
tion of its substrate(s). MARK kinase was previously
shown to phosphorylate tau in vitro (Drewes et al., 1997;Overexpression of PAR-1 in Drosophila Eye
Results in a Degeneration Phenotype Jenkins and Johnson, 2000). This, together with the fact
that expression of h-tau in Drosophila photoreceptorTo investigate the function of Drosophila PAR-1 in the
nervous system, we overexpressed the longest isoform neurons caused similar eye degeneration (Jackson et
al., 2002; Wittmann et al., 2001), led us to investigateof PAR-1 in the eye using the UAS-GAL4 system (Brand
and Perrimon, 1993; Sun et al., 2001). Targeted overex- the relationship between tau and PAR-1 in the process.
A fly tau homolog was recently shown to be expressedpression of PAR-1 to photoreceptor neurons using the
sevenless-GAL4 line resulted in eye degeneration in in the nervous system (Heidary and Fortini, 2001), but
no information on its loss-of-function or overexpressionnewly emerged adult flies. Strong PAR-1 expression
lines exhibited severely reduced eyes, with fused omma- phenotype is available. We used a chromosomal defi-
ciency associated with Tp(3;Y)R97 to test possible ge-tidia and missing inter-ommatidial bristles, as revealed
by scanning electron microscopy (SEM) analysis (Figure netic interaction between endogenous fly tau and
PAR-1. Through single embryo PCR analysis, we con-1C). Weak or mild expression lines had slightly reduced
eyes, which appeared rough and had disordered omma- firmed that this deficiency deletes fly tau. In flies overex-
pressing the strong PAR-1 transgene and heterozygoustidia and occasional missing bristles (Figure 1B). How-
ever, in flies that express two copies of the weak PAR-1 for the chromosomal deficiency, the eye degeneration
phenotype was partially suppressed (Figure 2B). Thistransgene, the eye degeneration phenotype became
more severe, similar to that observed in the strong ex- suggests that endogenous fly tau may mediate PAR-1-
induced eye degeneration phenotype.pression line (data not shown). Thus, overexpression
of PAR-1 using the sevenless-GAL4 driver causes eye We next tested for possible genetic interaction be-
tween fly PAR-1 and h-tau. Overexpression of the fourdegeneration in a dosage-dependent manner. No effect
was observed when PAR-1 KN, which contains an inacti- C-terminal tandem repeats (4R) isoform of h-tau con-
taining the R406W mutation (henceforth referred to asvating point mutation in the kinase domain, was ex-
pressed under sevenless-GAL4 control (Figure 1D). This h-tauM), which is associated with a familial form of
FTDP-17 (Hutton et al., 1998; Wittmann et al., 2001),indicates that the kinase activity of PAR-1 is required
for inducing the eye degeneration phenotype. caused a moderate eye degeneration phenotype (Figure
2C). Coexpression of the weak PAR-1 transgene, whichStaining of eye sections revealed that loss of photore-
ceptor neurons is associated with the eye degeneration by itself had a small effect on eye morphology (Figure
1B), enhanced h-tauM toxicity and resulted in smallerphenotype (Figures 1E and 1F). Since sevenless-GAL4
is expressed in the early developing eye disc and is later sized eyes (Figure 2D). The effect of the genetic interac-
tion is also reflected by the extent of photoreceptorexpressed in photoreceptor neurons as well as non-
neuronal pigment and cone cells, the loss of photore- neuron loss. As shown in Figure 2G, PAR-1 and h-tauM
coexpressing flies showed a greater neuronal loss (15%,ceptor neuron phenotype could be due to progressive
neurodegeneration or developmental perturbation of n  1050, 5 samples) than files expressing h-tauM (6%,
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Figure 1. Eye Degeneration Phenotypes
Caused by Overexpression of PAR-1
(A–D) SEM of a wild-type eye (A) and trans-
genic eyes overexpressing a weak PAR-1
transgene (B), a strong PAR-1 transgene (C),
or PAR-1 KN (D). Insets in (A) and (B) are
higher magnification views of ommatidia
and bristles.
(E–H) Toluidine blue staining of photorecep-
tor neurons. The genotypes are wild-type (E),
sev-GAL4UAS-PAR-1 (F), elav/ (G), elav-
GAL4UAS-PAR-1 (H). Arrows point to om-
matidia with missing photoreceptor neurons.
(I–L) SEM showing eye phenotypes induced
by elav-GAL4- or heat shock-GAL4-driven
PAR-1 overexpression. The genotypes are:
elav/ (I), elav-GAL4UAS-PAR-1 (J), heat
shock GAL4UAS-PAR-1 (K and L). The sam-
ple in (K) is heat shocked around first instar
larvae stage, whereas the one in (L) at pu-
pae stage.
(M–P) Toluidine blue staining of photorecep-
tor neurons in heat shock-GAL4UAS-PAR-1
flies. The samples are either non-heat shocked
(M) or heat shocked at first instar larvae (N),
pupae (O), or adult (P) stages. Arrows point
to ommatidia with missing photoreceptor
neurons.
n  1050, 5 eye samples) or PAR-1 (0.9%, n  1050, clonal antibodies such as AT100, which recognizes a
5 eye samples) alone. Interaction between PAR-1 and disease-specific phospho-epitope (Augustinack et al.,
h-tauM was also observed in cholinergic neurons in the 2002; Zheng-Fischhofer et al., 1998). Using AT100 anti-
CNS, where coexpression of PAR-1 and h-tauM resulted body, it was found that while a low level, diffused distri-
in profound vacuole formation in both the cell bodies bution of phospho-tau immunostaining was evident in
and neuronal processes, whereas expression of h-tauM photoreceptor neurons expressing h-tau alone, coex-
alone caused only mild vacuole formation in cell bodies pression of GSK-3 and h-tau promoted the appearance
and PAR-1 alone had little effect (Figures 2H and 2I). of prominent AT100-positive, NFT-like structures (Jack-
Thus, elevated expression of fly PAR-1 enhances the son et al., 2002). In contrast, coexpression of PAR-1 and
toxic effects of h-tauM. We next tested whether PAR-1 h-tauM did not produce obvious NFT-like aggregates
and wild-type h-tau genetically interact in the eye. Over- in either photoreceptor neurons or cholinergic neurons
expression of wild-type h-tau also caused a rough eye (Figure 2M). This suggests that some soluble, nonaggre-
phenotype, as reported previously (Jackson et al., 2002). gated forms of h-tauM may mediate the enhanced toxic
Coexpression of wild-type h-tau and a PAR-1 transgene effects of PAR-1 coexpression.
resulted in an exacerbated phenotype compared to ex-
pression of either gene alone (Figures 2J–2L). Thus, in-
creased expression of fly PAR-1 enhances the toxic PAR-1 Directly Phosphorylates h-tau and Fly
effects of both wild-type and mutant forms of h-tau. Tau In Vitro and In Vivo
In immunohistochemical analyses using a battery of
phosphorylation-sensitive tau antibodies, we observedOverexpression of PAR-1 Enhances Tau Toxicity
that PAR-1 overexpression resulted in a marked in-without Promoting NFT Formation
crease in the level of 12E8-positive h-tauM. The 12E8In AD and related tauopathies, NFT formed by the aggre-
gation of fibrillar forms of tau can be identified by mono- antibody specifically detects pS262 and pS356 in the
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Figure 2. Genetic Interactions between PAR-1
and Fly Tau and h-tau
(A–D) SEM of transgenic fly eyes expressing
a strong PAR-1 transgene (A), a strong PAR-1
transgene and heterozygous for a chromo-
somal deficiency that removes fly tau (B),
h-tauM (C), or h-tauM together with a weak
PAR-1 transgene (D).
(E–F) Toluidine blue staining of photoreceptor
neurons in transgenics expressing h-tauM (E)
or coexpressing h-tauM and a weak PAR-1
transgene (F). Arrows point to ommatidia with
missing photoreceptors.
(G) Quantitative analysis of photoreceptor
neuron loss. Asterisks indicate p  0.01 in
Student’s t test.
(H and I) Tau immunostainings of transgenic
brain expressing h-tau (H) or coexpressing
h-tau and PAR-1 (I). Arrows in (I) indicate vac-
uoles within the processes of the giant
interneuron commissure.
(J–L) SEM of transgenics expressing wild-type
h-tau (J), PAR-1 (K), or h-tau and PAR-1 (L).
(M and N) AT100 immunostaining of trans-
genic fly brain coexpressing PAR-1 and
h-tauM (M) or Shaggy and h-tauM (N). Sev-
enless-GAL4 driver was used in (A)–(F),
(J)–(L), and (N), Cha-GAL4 was used in (H),
(I), and (M).
MT binding domain of h-tau (Seubert et al., 1995). Bio- h-tauM as standard in Western blot analysis of total
brain extracts with 12E8 antibody and T14 antibody,chemical and cell culture studies have implicated MARK,
GSK-3, PKA, and CaMKII in phosphorylating these sites which measures total tau level. Three independent ex-
periments indicated that approximately 20% of total(Drewes et al., 1995; Litersky et al., 1996; Moreno et al.,
1995), but no animal study is yet available to validate h-tau was phosphorylated at S262/S356 sites in h-tauM
transgenic flies and this was increased to approximatelythese kinases as the physiological kinase for these sites.
We found that transgenic flies coexpressing PAR-1 and 80% in h-tauM and PAR-1 coexpression flies (Figure 3H).
The conservation of S262/S356 and their flanking resi-h-tauM stained robustly with 12E8 (Figure 3A). Flies ex-
pressing h-tauM alone also exhibited strong staining dues between h-tau and fly tau suggests that 12E8 may
also recognize phosphorylated fly tau. Indeed, a basalwith 12E8, albeit at a lower level (Figure 3B). This was
confirmed by Western blot analysis (Figure 3E). To esti- level of 12E8 staining was detected in wild-type flies
(Figure 3D). In flies that overexpress PAR-1, the level ofmate the level of h-tauM phosphorylation at S262/S356
sites, we used 12E8 antibody-immunoprecipitated 12E8 staining was significantly elevated (Figure 3C). This
Sequential Kinase Action Regulates Tau Toxicity
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Figure 3. PAR-1 Directly Phosphorylates Fly Tau and h-tau at 12E8 Epitope Sites
(A–D) 12E8 immunostaining of cholinergic nerve terminals in the optic medulla of Cha-GAL4-driven transgenics expressing h-tauM and PAR-1
together (A), h-tauM (B), PAR-1 (C), or wild-type control (D).
(E) Western blot analysis demonstrating increased 12E8-positive h-tauM (top) or endogenous fly tau (bottom) after PAR-1 expression. Phosphor-
ylation-independent antibody T14 (top) or a nonspecific crossreacting band (asterisk in bottom panel) was used as loading controls. The
graph indicates PAR-1-induced increase of 12E8-positive fly tau is significant.
(F) In vitro kinase assay using proteins immunoprecipitated by preimmune serum (Pre) or PAR-1 antibody (PAR-1). After the kinase reaction,
the GST-tau fusion proteins were probed with 12E8 antibody.
(G) In vitro kinase assay using PAR-1 or PAR-1 KN. Arrows and asterisk mark GST-tau fusion proteins and IgG, respectively. The GST-tau
substrates used in the kinase reactions are underlined.
(H) Estimation of level of phosphorylation in h-tauM only and h-tauM/PAR-1 coexpression flies. 12E8-positive h-tauM was immunoprecipitated
from h-tauM or h-tauM/PAR-1 transgenic brain extracts and 50 and 100 arbitrary units of the precipitated material were run together with 25
and 50 arbitrary units of the total brain extracts and probed with 12E8 and T14 antibodies. Asterisks and arrows indicate IgG bands and tau
bands, respectively. The ratio of 12E8/T14 signals was used to estimate the degree of phosphorylation. The graph represents quantitative
analysis of western results. Asterisk indicates p  0.01 in Student’s t test.
was also confirmed by Western blot analysis (Figure 3E). PAR-1, these GST-tau fusion proteins did not react with
12E8. Immunoreaction with 12E8 was readily detectedThus, overexpression of PAR-1 can lead to elevated
phosphorylation of both h-tauM and fly tau at the two after incubation with PAR-1 (Figure 3F). When the ki-
nase-negative form of PAR-1 (PAR-1 KN) was used inSer residues recognized by 12E8.
To test whether PAR-1 directly phosphorylates tau at the assay, 12E8 immunoreactivity was barely detectable
(Figure 3G). Together, these experiments demonstratethese sites, we performed in vitro kinase assays using
purified PAR-1 and bacterially expressed recombinant that PAR-1 directly phosphorylates h-tau and fly tau to
generate pS262 and pS356 residues recognized byglutathione-S-transferase (GST) fusion proteins of wild-
type h-tau and fly tau. Without preincubation with 12E8.
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cant portion of neurons in par-1/h-tauM clones
(13%, n  763, 8 brain samples) stained positive in
TUNEL assay (Figure 4A). In contrast, only 4% of neu-
rons in par-1/h-tauM clones (n936, 8 brain samples)
stained positive, a level similar to that observed in
par-1/h-tauM (n  476, 5 brain samples) and par-1/
h-tauM (n  1028, 5 brain samples) clones (Figures 4B
and 4E). The latter may represent the endogenous level
of TUNEL staining in fly brain under our experimental
conditions.
We next analyzed the effect of removing PAR-1 activ-
ity on the phosphorylation state of h-tauM at the 12E8
sites. The majority of neurons in par-1/h-tauM clones
(63%, n  631, 6 brain samples) were 12E8 positive
(Figure 4C). The lack of detectable 12E8 staining in the
remaining neurons may reflect cell type-specific varia-
tions in PAR-1 kinase activity or an unidentified phos-
phatase activity. In contrast, only a small fraction of
neurons in par-1/h-tauM clones were 12E8 positive
(5%, n 818, 6 brain samples) (Figures 4D and 4F). We
interpret the residual 12E8 staining in par-1/h-tauM
clones as a result of the perdurance of PAR-1 protein
or phosphorylation of h-tauM at S262 and S356 by other
kinases. Together, these results show that PAR-1 is the
major in vivo kinase that phosphorylates h-tauM at the
12E8 sites and this phosphorylation event is important
for conferring h-tauM toxicity.
Mutating PAR-1-Dependent Phosphorylation
Sites Abolishes h-tauM Toxicity
To further demonstrate the key effect of phosphorylationFigure 4. PAR-1 Activity Is Required for h-tauM Phosphorylation
by PAR-1 in conferring h-tauM toxicity, we made Alaand Toxicity
substitutions in PAR-1 phosphorylation sites (S262A and(A and B) Cortical neurons in par-1/h-tauM (A) and par-1/
h-tauM (B) MARCM clones were double-labeled for GFP (green) S356A) and assessed the effects of these mutations.
and TUNEL (red). Arrows point to TUNEL-positive nuclei. Overexpression of h-tauMS262A/S356A (referred to as
(C and D) Neurons in par-1/h-tauM (C) and par-1/h-tauM (D) S2A) in photoreceptor neurons had little effect on eye
MARCM clones in the optic lamina were double-labeled for GFP morphology or photoreceptor number (Figures 5C and
(green) and 12E8 (red). Arrows point to 12E8-positive swellings in
5D), although Western blot analysis showed that compa-neuronal processes.
rable amounts of tau protein were produced between(E and F) Quantification of TUNEL-positive (E) and 12E8-positive (F)
neurons within corresponding MARCM clones. Asterisks indicate S2A and h-tauM transgenic flies (Figure 5E). Since S2A
p  0.01 in Student’s t test. could still associate with neuronal microtubules in vivo
(Figures 5F and 5G), it is unlikely that the elimination of
h-tauM toxicity by the two point mutations is caused by
a drastic change in protein conformation. Instead, thesePAR-1 Function Is Required for Tau
results argue that the presence of the two phospho-Phosphorylation and Cytotoxicity
Ser residues in the MT binding domain is critical forWe next sought to address whether PAR-1 is normally
h-tauM toxicity.required for the phosphorylation and toxic effects of
h-tau under physiological conditions. Since null muta-
tions in par-1 are embryonic lethal, which prevented us Phosphorylation by PAR-1 Is Necessary for a
Subsequent Multisite Phosphorylation Eventfrom assessing the effects of loss of PAR-1 function
on tau toxicity in homozygous adult animals, we made We further characterized the overall in vivo phosphoryla-
tion profile of S2A (Figure 5H). As expected, S2A couldtissue clones of homozygous mutant cells in heterozy-
gous adult animals using mosaic analysis with a repress- no longer be recognized by 12E8. Surprisingly, Western
blot analysis indicated that phosphorylation of manyible cell marker (MARCM) (Lee and Luo, 1999). This tech-
nique allowed us to generate par-1 mutant clones other sites was also greatly reduced in S2A. Phosphory-
lation at several sites recognized by AD-relevant anti-expressing h-tauM under elav-GAL4 control and at the
same time positively mark these clones with a green bodies was virtually eliminated. These include AT100
(pT212 and pS214) and AT8 (pS202 and pT205) sites.fluorescent protein (GFP) reporter (par-1/h-tauM
clones). In parallel, we generated GFP-marked par-1/ In parallel, there was an increase in the level of tau
recognized by Tau-1 antibody, which detects unphos-h-tauM, par-1/h-tauM, and par-1/h-tauM clones.
To test the effect of removing PAR-1 function on tau phorylated S199 and S202 residues (data not shown).
The reduction of phosphorylation at S202 was also inde-toxicity, we performed TdT-mediated dUTP nick end
labeling (TUNEL) assays on the mosaic clones. A signifi- pendently confirmed by the pS202-specific CP13 anti-
Sequential Kinase Action Regulates Tau Toxicity
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Figure 5. Blocking PAR-1-Dependent Phos-
phorylation at 12E8 Sites Leads to h-tauM
Hypophosphorylation and Diminished Tox-
icity
(A and C) SEM of transgenic eyes expressing
h-tauM (A) or S2A (B).
(B and D) Toluidine blue staining of photore-
ceptor neurons in transgenics expressing
h-tauM (B) or S2A (D). Arrows point to omma-
tidia with missing photoreceptors.
(E) Western blot analysis showing compara-
ble expression of S2A and h-tauM in trans-
genic brain extracts. Reprobing with 22C10
antibody serves as loading control.
(F and G) Larval motor neuron axons were
immunostained for S2A (F) and tubulin (G) to
show their colocalization.
(H) Western blot analysis of wild-type or
h-tauM and S2A transgenic head extracts us-
ing T14 antibody and a series of phosphoryla-
tion-dependent tau antibodies.
(I) Western blot analysis of fly heads with
par-1/ or par-1/ mosaic eyes express-
ing h-tauM.
Sevenless-GAL4 driver was used in all panels
except (F) and (G), where elav-GAL4 was
used.
body. Phosphorylation at PHF-1 (pS396 and pS404) GSK-3 and Cdk5 Act Downstream of PAR-1
in the Multistep Phosphorylation Processsites showed a moderate reduction. It should be noted
that not all phosphorylation sites in tau are affected by Recent transgenic animal studies have implicated two
kinases, GSK-3 and Cdk5, in the phosphorylation ofthe S262A/S356A mutations. For example, phosphoryla-
tion at T181 recognized by AT270 antibody was not af- tau in vivo. Analyses of tau phosphorylation status in
transgenic mice overexpressing GSK-3 or Cdk5 havefected.
The results described above suggest that phosphory- detected increased phosphorylation at certain sites pre-
viously identified as their in vitro phosphorylation sites.lation by PAR-1 at S262 and S356 is required for the
subsequent phosphorylation events. To test this possi- For example, S202 and PHF-1 sites (S396 and S404)
have been shown to be prominent Cdk5 and GSK-3bility further, we examined the phosphorylation state
of h-tauM when PAR-1 function is removed. For this phosphorylation sites, respectively, and the two kinases
may have overlapping specificity at these sites (Liu etpurpose, we used a modified FLP/FRT technique to gen-
erate mosaic eyes enriched for par-1 mutant clones al., 2002; Lovestone et al., 1994; Lucas et al., 2001;
Michel et al., 1998; Noble et al., 2003; Patrick et al.,(Newsome et al., 2000). The h-tauM transgene was uni-
formly expressed in these eyes under sevenless-GAL4 1999). We tested whether these sites in h-tauM were
also phosphorylated by the corresponding fly kinases.control. On average, more than half of the mosaic eye
were composed of homozygous par-1 mutant clones. The activity of Cdk5 is regulated by its binding with
neuron-specific activators. Overexpression of Drosoph-Western blot analysis on single fly heads indicated that
h-tauM phosphorylation at 12E8, AT8, and AT100 epi- ila P35 activator has been shown to elevate endogenous
Cdk5 activity (Connell-Crowley et al., 2000). In P35 andtope sites was significantly reduced in par-1/ mosaic
eyes compared to par-1/eyes (Figure 5I). Together h-tauM coexpression flies, we observed that the level of
phosphorylation at S202 recognized by CP13 antibody iswith the Western blot analysis of S2A transgenic flies,
these data suggest that phosphorylation by PAR-1 at elevated. In addition, phosphorylation at AT270 sites
was also significantly increased. Phosphorylation atS262 and S356 is a prerequisite for the subsequent
phosphorylation by other kinases in a temporally or- AT100, AT180, and PHF-1 sites was relatively unchanged
(Figure 6D). Thus, phosphorylation at S202 and T181dered phosphorylation process.
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Figure 6. GSK-3 and Cdk5 Act Downstream
of PAR-1 in a Sequential Phosphorylation
Process
(A–C) SEM of transgenic eyes expressing
h-tauM alone (A), coexpressing h-tauM and P35
(B), or coexpressing h-tauM and Shaggy (C).
(D) Western blot analyses comparing tau phos-
phorylation between h-tauM and h-tauM/
PAR-1, h-tauM/P35, or h-tauM/Shaggy trans-
genics. The bar graphs show quantitative anal-
ysis of relative phosphorylation level changes
after PAR-1, P35, or Shaggy coexpression.
(E–G) SEM of S2A transgenic eyes coex-
pressing PAR-1 (E), P35 (F), or Shaggy (G).
Sevenless-GAL4 driver was used in all panels.
responds to changes in Cdk5 levels. The eye morphol- PHF-1, CP13, AT180, and AT100 sites (Figure 6D). We
conclude that these phospho-epitopes contain GSK-3ogy of P35 and h-tauM coexpressing flies appeared
similar to that of flies expressing h-tauM alone (Figures phosphorylation sites and that elevated phosphoryla-
tion at these sites enhances tau toxicity.6A and 6B), suggesting that elevated Cdk5 activity does
not significantly enhance tau toxicity. We next analyzed The fact that many of the above-tested phosphoryla-
tion sites for GSK-3 and Cdk5 kinases are affected inShaggy and h-tauM coexpression flies. As reported pre-
viously (Jackson et al., 2002), coexpression of Shaggy S2A suggests that phosphorylation by the two kinases
is regulated by prior PAR-1 action. To test this ideaand h-tau resulted in enhanced eye degeneration phe-
notypes (Figure 6C). In the coexpression flies, we ob- further, we analyzed the phosphorylation status of
GSK-3 and Cdk5 phosphorylation sites in PAR-1 andserved significantly increased tau phosphorylation at
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h-tauM coexpression flies. In addition to 12E8 sites,
significant increase of phosphorylation was observed
at CP13 and PHF-1 sites in these flies (Figure 6D). In
contrast, phosphorylation at other sites such as AT100
sites was little changed, suggesting that PAR-1 is not
a rate-limiting factor for these phosphorylation events.
Since in vitro kinase assays showed that PAR-1 is inca-
pable of directly phosphorylating the CP13 and PHF-1
sites (data not shown), the elevated phosphorylation at
these sites in PAR-1 coexpressing flies are likely medi-
ated by downstream kinases such as Cdk5 and GSK-3.
We further tested whether coexpression of PAR-1,
GSK-3, or Cdk5 has any modulating effect on S2A toxic-
ity in vivo. PAR-1 and S2A coexpression flies showed
a mild rough eye phenotype similar to PAR-1 overex-
pression alone (Figure 6E, compare to Figure 1B), indi-
cating that PAR-1 overexpression does not confer addi-
tional toxicity to S2A. Cooverexpression of GSK-3 or
Cdk-5 also did not change S2A toxicity (Figures 6F and
6G). These results further support the notion that phos- Figure 7. Effects of S202A Mutation on h-tauM Phosphorylation
and Toxicityphorylation by PAR-1 at S262 and S356 is a prerequisite
for the subsequent phosphorylation by downstream ki- (A and B) SEM of transgenic eyes expressing h-tauM (A) or
S202A (B).nases such as GSK-3 and Cdk5 to generate toxic tau
(C and D) Toluidine blue staining of photoreceptors in transgenicsspecies.
expressing h-tauM (C) or S202A (D).
(E) Western blot analysis of transgenic head extracts expressing
Mutating a Downstream Cdk5/GSK-3 h-tauM or S202A.
Phosphorylation Site (S202A) Has Much Smaller Sevenless-GAL4 driver was used in all panels.
Effects on Overall tau Phosphorylation
and Toxicity than S2A Mutations
Since the S2A mutation disrupts tau phosphorylation erative diseases are still poorly defined. Studying these
at multiple downstream sites, it does not allow us to diseases in model organisms offers the power of genetic
distinguish the contribution of individual phosphoryla- analysis to dissect the disease processes. In this study,
tion sites to tau toxicity. We wished to address this we have shown that PAR-1, the fly homolog of mamma-
issue by making point mutations in the downstream lian MARK kinase, plays a central role in conferring tau
phosphorylation sites. We focused on the S202 site be- toxicity in vivo. Our study reveals PAR-1 function in
cause it is phosphorylated by Cdk5 and GSK-3 in vivo triggering a temporally ordered phosphorylation pro-
and because AT8 antibody, which is sensitive to phos- cess that is responsible for generating toxic forms of
phorylation at this site, was considered an Alzheimer- tau. This multisite phosphorylation process involves
diagnostic antibody. We generated transgenic flies that downstream kinases such as Cdk5 and GSK-3, whose
express h-tauM containing an Ala substitution at S202 action depends on prior phosphorylation of h-tau by
(S202A). Western blot analysis demonstrated that, as PAR-1. A nonphosphorylatable mutation at S202, one
predicted, S202A protein was no longer recognized by of the downstream GSK-3/Cdk5 target sites whose
CP13 or AT8 antibodies. Significantly, phosphorylation phosphorylation depends on prior PAR-1 action, has a
at 12E8, AT100, PHF-1, AT180, and AT270 sites was much smaller impact on overall tau phosphorylation and
unaffected by S202A mutation (Figure 7E). This suggests toxicity than mutations at PAR-1 phosphorylating sites.
that unlike S262 and S356 sites, the phosphorylation This strongly supports the initiator role of PAR-1 in gen-
state of S202 does not influence that of other sites. erating toxic species of tau and further implies that the
Examination of external eye morphology by SEM and toxic form of tau may be phosphorylated at a subset or
photoreceptor staining of eye sections showed that, all of the other downstream sites.
unlike S2A, S202A is as toxic as h-tauM (Figures 7B and Our results indicate that tau phosphorylation by
7D). This suggests that phosphorylation by GSK-3 and PAR-1/MARK represents one of the earliest events in
Cdk5 at S202 site plays a rather limited role in conferring the pathological process. Consistent with this notion,
tau toxicity. This result supports the notion that PAR-1 the 12E8 epitope sites are phosphorylated in all the
plays an initiator role in the pathogenic phosphorylation isoforms of h-tau found in AD brain (Augustinack et al.,
process and further suggests that phosphorylation at 2002; Seubert et al., 1995). Relatively little is known
downstream sites other than S202 or a combination about the upstream events that act through PAR-1/
of those downstream phosphorylation events makes a MARK to regulate h-tau phosphorylation in the disease
major contribution to tau toxicity. process. Understanding how PAR-1/MARK kinases are
regulated during normal development may provide
some clues. PAR-1 belongs to a group of evolutionarilyDiscussion
conserved PAR proteins that control cell polarity. Genet-
ics studies have shown that PAR-1 is regulated by aThe molecular mediators and cellular events that con-
tribute to the pathogenesis of most human neurodegen- PAR-3/PAR-6/aPKC protein complex (Pellettieri and
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Seydoux, 2002). Recently, the mammalian PAR-3 and theless indicate that phospho-tau constitutes a sub-
PAR-6 proteins have been shown to regulate hippocam- stantial fraction of the total protein. Future genetic stud-
pal neuronal polarity through interaction with the phos- ies in Drosopila could help reveal the exact mechanisms
phatidylinositol 3-kinase signaling pathway (Shi et al., of phospho-tau toxicity.
2003). Furthermore, recent biochemical studies have Rapid progresses in our understanding of the biogen-
identified a protein kinase capable of activating MARK/ esis of amyloid plaques have led to efforts to develop
PAR-1 (Timm et al., 2003). It would be interesting to AD therapy based on inhibition of the processing and
test whether these factors may regulate h-tau toxicity aggregation of A or clearance of mature amyloid
through PAR-1. plaques. In view of the role of tau in the disease process,
It was previously shown that PAR-1 regulates the it might be more rational to target both amyloid and tau
Wingless/Wnt pathway in Drosophila and Xenopus by pathologies in therapeutic approaches. This study is
phosphorylating the core component Dishevelled (Sun beginning to dissect the relative contribution by individ-
et al., 2001). It is thus interesting that GSK-3, another ual phosphorylation events to tau toxicity. Further analy-
core component of Wingless pathway, acts downstream sis will identify the kinases acting downstream of PAR-1
of PAR-1 to phosphorylate h-tau. These results are con- and playing dominant roles in conferring tau toxicity.
sistent with the notion that the Wingless pathway may Future studies will also test whether deregulation of the
be involved in regulating tau phosphorylation (Jackson PAR-1-initiated multisite phosphorylation process may
et al., 2002). It has been proposed that the pathway underlie certain idiopathic tauopathies and whether
components are utilized differently in tau phosphoryla- PAR-1 and the downstream kinases could serve as ther-
tion than in canonical Wnt signaling. Our data indicate apeutic targets.
that PAR-1 and GSK-3 directly phosphorylate tau in an
Experimental Proceduresordered fashion, with PAR-1 action preceding that of
GSK-3. One parsimonious explanation for the require-
Fly Stocks and Geneticsment of prior phosphorylation by PAR-1 is that PAR-1
All general fly stocks and GAL4 lines were obtained from thephosphorylation reduces the affinity of tau for MT and
Bloomington Drosophila stock center. The UAS-tau(R406W) and the
releases it from the MT network, therefore allowing easy Cha-GAL4 lines were kindly provided by Drs. Mel Feany and Paul
access by other kinases. If that is the case, the mecha- Salvaterra, respectively. SEM analysis of eye morphology was per-
nism may operate in a region-specific manner since formed essentially as described (Jackson et al., 2002). In most cases,
transheterozygous flies from a cross between a UAS line and acertain phosphorylation sites do not depend on prior
GAL4 line were used.PAR-1 action. Our data are also consistent with the
idea that PAR-1 phosphorylation at 12E8 sites provides
Histology and Immunohistochemistrydocking sites for intermediary kinase(s) and/or adaptor
Immunohistochemical analyses of adult fly brain was performed as
molecule(s), which facilitate subsequent phosphoryla- described (Yang et al., 2003). The primary antibodies used were
tion by GSK-3 and Cdk5. It appears that the phosphory- 3E6 monoclonal antibody against GFP (1:1,000), rabbit polyclonal
lation at certain downstream sites is achieved through antibody against nonphosphorylated form of h-tau (1:2,500), 12E8
monoclonal antibody against h-tau (1:4,000), AT100 monoclonal an-a complex process. For example, phosphorylation at
tibody against PHF tau (1:1000).AT100 sites depends on prior PAR-1 action, but PAR-1
For MARCM analysis, appropriate stocks were used to set upco-overexpression does not increase phosphorylation
crosses as described (Lee and Luo, 1999). Whole brain tissues were
at these sites. Instead, co-overexpression of GSK-3 can dissected out and immunostained. The primary antibodies used
lead to increased phosphorylation at AT100 sites. Previ- were rabbit anti-GFP and 12E8. Nuclear DNA fragmentation was
ous in vitro studies have shown that the generation of analyzed by TUNEL staining. Following TUNEL reaction, samples
were immunostained for GFP as described above and visualizedAT100 epitope requires a PHF-like conformation of tau
with Cy2-conjugated secondary antibody. Images were taken with aand the sequential phosphorylation by GSK-3 and PKA
Zeiss confocal microscope. For quantitative analysis, whole-mount(Zheng-Fischhofer et al., 1998). It remains to be deter-
brain samples were scanned with confocal microscope, and TUNEL-mined whether GSK-3 and PKA act downstream of
or 12E8-positive cells among GFP-positive clones were counted in
PAR-1 to phosphorylate AT100 sites in flies. the merged images.
Recent studies suggest that synaptic dysfunction may
be one of the earliest events in the pathogenesis of In Vitro Phosphorylation
AD (Selkoe, 2002). It is reasonable to speculate that DNA sequences corresponding to full-length h-tau and fly tau, or
the MT binding domains of fly tau (d-tau MTBD), were amplified byabnormally phosphorylated tau may contribute to syn-
polymerase chain reaction and inserted directionally into pGEX 5X1aptic dysfunction in AD. MT is known to be essential in
to produce in-frame GST fusion constructs. Bacterially expressedsynaptic vesicle transport during neurotransmission and
proteins were affinity purified using glutathione agarose. To purifyin the formation and maintenance of synaptic structures.
active PAR-1 kinase, 0–16 hr mixed stage w embryonic extract was
Given the known function of tau in MT binding, it is subject to immunoprecipitation with PAR-1 antibody or preimmune
conceivable that phosphorylation may induce the de- antiserum. Immunocomplexes were washed first with lysis buffer
tachment of tau from MT, thereby affecting MT dynamics and then with kinase buffer. The kinase reactions were carried out
essentially as described (Riechmann et al., 2002). Similarly, to ana-and disrupting synaptic functions. Alternatively, phos-
lyze the effect of PAR-1 (KN) on tau phosphorylation, extracts of flypho-tau could acquire certain new activities unrelated
heads expressing Myc-tagged PAR-1 KN or wild-type PAR-1 wereto MT binding, such as gaining affinity for some unidenti-
subject to immunoprecipitation with Myc antibody. Immunoprecipi-fied factors at the synapse and interfering with their
tates were used in kinase reactions.
function. While our estimates of the levels of tau phos-
phorylation at S262/S356 sites in h-tauM only and Site-Direct Mutagenesis and Transgenics
h-tauM and PAR-1 coexpression transgenic flies do not A cDNA clone encoding h-tau(R406W) was subject to site-directed
mutagenesis to change codons 262 and 356 from TCCs to GCCdistinguish between these two possibilities, they never-
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and GCT and codon 202 from TCC to GCC to produce S2A and Drewes, G., Trinczek, B., Illenberger, S., Biernat, J., Schmitt-Ulms,
G., Meyer, H.E., Mandelkow, E.M., and Mandelkow, E. (1995). Micro-S202A, respectively. Resulting S2A and S202A cDNAs were fully
sequenced and subcloned into pUAST vector for germline transfor- tubule-associated protein/microtubule affinity-regulating kinase
(p110mark). A novel protein kinase that regulates tau-microtubulemation. Multiple transgenic lines were obtained. Protein expression
levels were examined by Western blotting with monoclonal phos- interactions and dynamic instability by phosphorylation at the Alz-
heimer-specific site serine 262. J. Biol. Chem. 270, 7679–7688.phorylation-independent antibody T14 (1:500) as described below,
and representative lines expressing the highest level of S2A and Drewes, G., Ebneth, A., Preuss, U., Mandelkow, E.M., and Mandel-
S202A were used in subsequent studies. kow, E. (1997). MARK, a novel family of protein kinases that phos-
phorylate microtubule-associated proteins and trigger microtubule
Western Blotting disruption. Cell 89, 297–308.
To analyze the phosphorylation status of tau, dissected adult fly Feany, M.B., and Dickson, D.W. (1996). Neurodegenerative disor-
heads or larval brain and ventral nerve cords were homogenized in ders with extensive tau pathology: a comparative study and review.
a lysis buffer (10 mM Tris/Cl, pH 7.4, 150 mM NaCl, 5 mM EDTA, Ann. Neurol. 40, 139–148.
5 mM EGTA, 10% glycerol, 50 mM NaF, 1 mM Na3VOF3, 5 mM NaPPi, Foster, N.L., Wilhelmsen, K., Sima, A.A., Jones, M.Z., D’Amato, C.J.,5 mM DTT, 4 M urea, and a cocktail of protease inhibitors). Extracts
and Gilman, S. (1997). Frontotemporal dementia and parkinsonismwere mixed with SDS sample buffer, heated at 60C, centrifuged at
linked to chromosome 17: a consensus conference. Conference8,000 g for 5 min, and separated by 10% SDS-PAGE. Proteins were
Participants. Ann. Neurol. 41, 706–715.transferred to PVDF membranes and probed with primary antibod-
Goedert, M. (1998). Neurofibrillary pathology of Alzheimer’s diseaseies: T14 (1:1000), 12E8 (1:4000), AT270 (1:1000), AT8 (1:500), AT100
and other tauopathies. Prog. Brain Res. 117, 287–306.(1:500), CP13 (1:500), PHF-1 (1:500), Tau1 (1:1000), and 22C10
(1:200). The membranes were incubated with peroxidase-labeled Goedert, M., Spillantini, M.G., Jakes, R., Crowther, R.A., Vanmeche-
anti-mouse IgG, and signals were detected with chemilumines- len, E., Probst, A., Gotz, J., Burki, K., and Cohen, P. (1995). Molecular
cence reagents. dissection of the paired helical filament. Neurobiol. Aging 16,
325–334.
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